Silver Book Fact

Use of an epidermal growth factor inhibitor in the treatment of metastatic colon cancer patients without the KRAS gene mutation saw survival rates of 15.6 months, compared to 5.6 months in those without the mutation.

Lievre, A, J Bachet, V Boige, A Cayre, D LeCorre, E Buc, et al. KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab. J Clin Oncol. 2008; 26(3): 374-9. http://www.ncbi.nlm.nih.gov/pubmed/18202412

Reference

Title
KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab
Publication
J Clin Oncol
Publication Date
2008
Authors
Lievre, A, J Bachet, V Boige, A Cayre, D LeCorre, E Buc, et al
Volume & Issue
Volume 26, Issue 3
Pages
374-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Death rates from breast cancer have steadily decreased in women since 1990. This decrease represents progress in both early detection and improved treatment.  
  • A modest 1% reduction in cancer mortality would be worth close to $500 billion. A cure for cancer (if one is feasible) would be worth around $50 trillion.  
  • Medicines Prevent Cancer Recurrence: New breast cancer drug greatly reduces recurrence and death (5 to 10 years after diagnosis in postmenopausal women)  
  • Baseline lung cancer screening would lead to more than 130,000 additional survivors in 2012.  
  • Following the current path, the lung cancer incidence rate will increase by 34% between 2003 and 2023. If an alternative path is taken, there will be 18.4% (92,000) fewer lung…